BRANFORD, Conn., May 4 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on novel drugs to treat serious neurological disorders, today announced that it is enrolling patients in an international, multi-center, placebo controlled Phase IIb study of its lead compound, Ganaxolone, as an adjunctive treatment in adults suffering from partial onset seizures. This marks the second indication for which Marinus is evaluating Ganaxolone. Ganaxolone is also currently being evaluated in a separate Phase IIb study in infants suffering from Infantile Spasms (also called West syndrome).
